Evidence map›Paper›PMID 27468058›Full record

ArticleThe New England journal of medicine2016

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.

Nicole E Basta, Adel A F Mahmoud, Julian Wolfson, Alexander Ploss, Brigitte L Heller, Sarah Hanna, Peter Johnsen, Robin Izzo, Bryan T Grenfell, Jamie Findlow and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020
    Guideline
  2. Pooled it
  3. Trial
  4. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017
    Trial
  5. Review
  6. Review
  7. Presentations at the UK National Immunisation Conference.Human vaccines & immunotherapeutics · 2022
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. A physician's guide to the 2-dose schedule of MenB-FHbp vaccine.Human vaccines & immunotherapeutics · 2019
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Cross-protection induced by VA-MENGOC-BC® vaccine.Human vaccines & immunotherapeutics · 2018
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nicole E BastaFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Adel A F MahmoudFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Julian WolfsonFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Alexander PlossFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Brigitte L HellerFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Sarah HannaFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Peter JohnsenFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Robin IzzoFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Bryan T GrenfellFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Jamie FindlowFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Xilian BaiFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Ray BorrowFrom the School of Public Health, University of Minnesota, Minneapolis (N.E.B., J.W.); Princeton University, Princeton, NJ (N.E.B., A.A.F.M., A.P., B.L.H., S.H., P.J., R.I., B.T.G.); National Institutes of Health Research and Policy for Infectious Disease Dynamics, Bethesda, MD (N.E.B., B.T.G.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (J.F., X.B., R.B.).
Princeton University · USPublic Health England · GBCenter for Disease Dynamics, Economics & Policy · USUniversity of Minnesota · US

Funding

Minnesota Population Center Science and Technical CoreP2CHD041023 · NICHD · UNIVERSITY OF MINNESOTA · PI THERESA LOUISE OSYPUK · 2016 to 2026
$4.3M
Scientific and Technical Computing CoreP2CHD047879 · NICHD · PRINCETON UNIVERSITY · PI SALGANIK, MATTHEW J. · 2014 to 2018
$2.0M
Antibody persistence after conjugate meningococcal group A vaccination in MaliDP5OD009162 · OD · UNIVERSITY OF WASHINGTON · PI BASTA, NICOLE ELAINE · 2011 to 2015
$1.9M
NICHD NIH HHS P2C HD041023NICHD NIH HHS P2C HD047879NIH HHS 1DP5OD009162NIH HHS DP5 OD009162
6 · The paper itself

Abstract

backroundIn December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure on the basis of special consideration by the Food and Drug Administration to respond to an outbreak of Neisseria meningitidis B at a U.S. university. Data suggested that vaccination would control the outbreak because isolates expressed antigens that were closely related to the vaccine antigens (factor H-binding protein [fHbp] and neisserial heparin-binding antigen). We quantified the immune responses induced by 4CMenB during the outbreak.

methodsWe conducted a seroprevalence survey among students to assess vaccination status and collect serum specimens to quantify titers of serum bactericidal antibodies (SBA) with an assay that included human complement (hSBA). We compared the proportion of vaccinated and unvaccinated participants who were seropositive for the outbreak strain and for one closely related reference strain (44/76-SL, which included fHbp) and one mismatched reference strain (5/99, which included neisserial adhesin A), both of which were used in vaccine development. Seropositivity was defined as an hSBA titer of 4 or higher.

resultsAmong the 499 participants who received two doses of the 4CMenB vaccine 10 weeks apart, 66.1% (95% confidence interval [CI], 61.8 to 70.3) were seropositive for the outbreak strain, although the geometric mean titer was low at 7.6 (95% CI, 6.7 to 8.5). Among a random subgroup of 61 vaccinees who also received two doses but did not have a detectable protective response to the outbreak strain, 86.9% (95% CI, 75.8 to 94.2) were seropositive for the 44/76-SL strain, for which there was a geometric mean titer of 17.4 (95% CI, 13.0 to 23.2), whereas 100% of these vaccinees (95% CI, 94.1 to 100) were seropositive for the 5/99 strain and had a higher geometric mean titer (256.3; 95% CI, 187.3 to 350.7). The response to the outbreak strain was moderately correlated with the response to the 44/76-SL strain (Pearson's correlation,0.64; P<0.001) but not with the response to the 5/99 strain (Pearson's correlation,-0.06; P=0.43).

conclusionsEight weeks after the second dose of the 4CMenB vaccine was administered, there was no evidence of an hSBA response against the outbreak strain in 33.9% of vaccinees, although no cases of meningococcal disease caused by N. meningitidis B were reported among vaccinated students. (Funded by Princeton University and others.).

Indexed as

Antibodies, BacterialDisease OutbreaksFemaleHumansMaleMeningitis, MeningococcalMeningococcal VaccinesNeisseria meningitidis, Serogroup BNew JerseySeroepidemiologic StudiesUnited StatesUniversitiesYoung Adult4CMenB vaccineAntibodies, BacterialMeningococcal Vaccines

Identifiers

PMID27468058
PMCPMC4992664
OpenAlexW2482948689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.